FILTER
LATEST INTERVIEWS
Dr. Siva Samy
CEO & CHIEF PRODUCT STRATEGIST, VALGENESIS
ValGenesis explains how it streamlines the validation process to allow real-time access to validation documents and data enabling various stakeholders to achieve compliance efficiently.
Michael Kauffman
CEO, KARYOPHARM THERAPEUTICS
GBR speaks to Karyopharm Therapeutics about the commercialization of XPOVIO.
Raymond Sinnah
PRESIDENT OF MINERAL SPECIALTIES DIVISION, SEQENS GROUP
Seqens group in Singapore explains on going expansion.
Chye Poh Chua
FOUNDER AND CEO, SHIPSFOCUS GROUP
ShipsFocus Group explains why the shipping industry is ripe for a digital revolution and how Singapore’s start-ups are preparing.
Fernando Barrio
GENERAL MANAGER, TECNOMINA
Tecnomina in Peru explains how it managed to achieve a bit of growth during a difficult year.
Heather Gamble
FOUNDER & CEO, WOMEN ON THE MOVE
Women On The Move explains how companies run by female entrepreneurs are set to play a more proportionate role in the mining industry’s supply chain.
Paolo Russolo
PRESIDENT, ASCHIMFARMA – FEDERCHIMICA
Aschimfarma explains to GBR how Italian producers of APIs are well positioned to strengthen the European drug supply chain.
Mathieu Savard
PRESIDENT, OSISKO MINING
Osisko Mining updates GBR on progress at the large Windfall gold project in Québec.
Eric Ostertag M.D., Ph.D.
CEO, POSEIDA THERAPEUTICS
Poseida Therapeutics explains how progress in gene therapy offers the possibility to provide single treatment cures for cancer and other genetic diseases.
Jaime Solano
TECHNICAL SALES DIRECTOR, TORSA
TORSA is an R&D company based in Spain with more than 20 years of experience developing solutions for different sectors, such as renewable energy, logistics and mining.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
